Malayala Srikrishna V, Papudesi Bhavani N, Sharma Rishika, Vusqa Urwat T, Raza Ambreen
Internal Medicine, Temple University Hospital, Philadelphia, USA.
Internal Medicine, Mercy Health, Philadelphia, USA.
Cureus. 2021 Oct 23;13(10):e18985. doi: 10.7759/cureus.18985. eCollection 2021 Oct.
Vaccination is now considered the best measure in minimizing the morbidity and mortality from the Covid-19 pandemic. Almost all the vaccines are considered safe except for minor and occasional side effects. Some of the commonly reported complications from the COVID-19 vaccines are vaccine-induced thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome/vaccine-induced pro-thrombotic immune thrombocytopenia syndrome. In this case report, we present a case of a 75-year-old female who had an uncomplicated first and second vaccine dose but developed VITT after the booster dose of the vaccine. The patient was treated with dexamethasone and platelet transfusions. So far no such cases have been reported after the third (booster) dose of the Pfizer-Biontech vaccine. With this case report, we present the case of the patient and discuss the literature related to vaccine-induced thrombocytopenia.
目前,接种疫苗被认为是将新冠疫情导致的发病率和死亡率降至最低的最佳措施。除了轻微和偶尔出现的副作用外,几乎所有疫苗都被认为是安全的。新冠疫苗常见的一些并发症包括疫苗诱导的血栓性血小板减少症(VITT)/血小板减少伴血栓形成综合征/疫苗诱导的促血栓免疫性血小板减少症综合征。在本病例报告中,我们介绍了一名75岁女性的病例,她在接种第一剂和第二剂疫苗时未出现并发症,但在接种加强针后出现了VITT。该患者接受了地塞米松和血小板输注治疗。到目前为止,辉瑞- BioNTech疫苗第三剂(加强针)后尚未报告此类病例。通过本病例报告,我们展示了该患者的病例,并讨论了与疫苗诱导的血小板减少症相关的文献。